Overview and registration fees

Hear the latest developments in thyroid pathology and oncology from nationally and internationally recognised experts in the field.

Please note that this event has now closed for further bookings. 

If you wish to attend the conference, please contact Tanya Whyte on 020 7451 6781 or email tanya.whyte@rcpath.org

Join us for a two-day update on endocrine pathology, covering topics (TBC) including: 

  • The Thyroid Cancer ‘Epidemic’
  • Pathological criteria for papillary thyroid carcinoma
  • Surgical approaches to thyroid cancer & pathology
  • Reporting thyroid FNA cytology using the UK ‘Thy’ system
  • WHO 2017 Classification of thyroid tumours 2017; NIFTP, FTUMP, WDTUMP, WDCa-NOS (emphasis on diagnostic pitfalls)
  • Risk stratification of thyroid cancer
  • Pitfalls in thyroid diagnosis & medicolegal issues
  • The Thyroid Patient. What the oncologist needs from pathology
  • Update on new therapies & clinical trials for thyroid cancer
  • Multidisciplinary working in thyroid disease
  • MDT’s, datasets & UK national guidelines. 
  • Case based discussions

Who should attend?

Consultant pathologists and senior trainees reporting thyroid pathology.

Online Bookings

RCPath & UKEPS Members: £288.00
Concessions: £150.00 Includes trainees, BMS, non-consultant Clinical Scientists, retired & nurses
Non-members: £357.00

One day rates now available. Please contact meetings@rcpath.org for more detail. 

Offline Bookings (cheque and invoice)

RCPath & UKEPS Members: £323.00
Concessions: £183.00 Includes trainees, BMS, non-consultant Clinical Scientists, retired & nurses
Non-members: £388.00

Please note that an administrative charge of £20.00 will be made on all cancellations and the total registration fee is forfeited if cancelled one working week before the event.



Day 1 - Thursday 6th February 2020 

  9.30     Registration

10.00     Introduction and welcome

10.05     The Thyroid Cancer ‘Epidemic’. Professor Manuel Sobrinho-Simoes, Porto 

10.30     WHO 2017- update on encapsulated follicular patterned lesions, NIFTP, FTUMP, WDTUMP, WDCa-NOS with emphasis on diagnostic pitfalls and how to avoid them. Professor Giovanni Tallini, Bologna 

11.30     Refreshments

12.00     Reporting thyroid FNA using the UK Thy system with emphasis on practical application. Dr Sarah Johnson, Newcastle 

12.40     Diagnosing papillary thyroid carcinoma with emphasis on non-encapsulated variants and illustrative cases. Dr Mufaddal Moonim, London 

13.20     Lunch

14.00     Risk stratification of thyroid cancer with emphasis on high grade cases and illustrative example. Dr Ronald Ghossein, New York 

15.00     Surgical approaches to thyroid cancer and what the surgeon needs from the pathologist before and after surgery. Mr Sabapathy Balasubramanian, Sheffield 

15.50     Refreshments

16.10     Unexpected pathology in the thyroid: case based discussions. Professor Giovanni Tallini and Professor Manuel Sobrinho-Simoes 

17.10     Closing remarks

Day 2 - Friday 7th February 2020 

  9.00     Registration

  9.30     Welcome

  9.35     Pitfalls and medicolegal issues in thyroid diagnosis and how to avoid them, with illustrative cases. Dr Ronald Ghossein, New York

10.35     Refreshments

11.00     The thyroid cancer patient: what the oncologist needs from pathology and an update on new therapies and clinical trials. Professor Jonathan Wadsley, Sheffield 

11.55     Why the Thyroid Multidisciplinary Team is so important with emphasis on common practical issues. Dr David Poller, Portsmouth

12.55     Closing remarks

13.00     Meeting close


To be held at the Royal College of Pathologists, 6 Alie Street, London E1 8QT.


2nd Bi-Annual UK Endocrine Pathology Society/RCPath Endocrine Pathology Update

  • Professor Manuel Sobrinho-Simoes, Porto

    Manuel Sobrinho Simões, MD, PhD, HonFRCPath is Emeritus Professor of Pathology and Director of the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP). MSS was President of the European Society of Pathology from 1999 to 2001, after having been Secretary from 1989 to 1997. MSS is co-author of about 400 papers (h factor 60) and many chapters of the last editions (1988, 2004 & 2017) of the WHO Book on Endocrine Tumours. MSS was considered the most influential pathologist in 2015 by The Pathologist and co-created, in 1992, the on-going very active European School of Pathology.

  • Dr Mufaddal Moonim, London

    Dr Mufaddal Moonim is consultant Histopathologist at Guy’s & St Thomas’ Hospitals NHS Foundation Trust, London and prior to this worked for many years at the Tata Memorial Cancer center in Mumbai India. He is lead for Haematopathology and Endocrine Pathology at GSTT. He is also meetings secretary for the UK Endocrine Pathology Society (UKEPS) and co-author of the RCPath Adrenal tumour dataset. His interests include adrenal tumours, SDHB expression in Phaeochromocytoma, thyroid tumours, thyroid FNA and minimally invasive diagnostics.

  • Dr Sarah J Johnson, Newcastle upon Tyne

    Consultant Cyto/histopathologist at the Royal Victoria Infirmary in Newcastle upon Tyne. Lead for Endocrine Pathology for Newcastle upon Tyne Hospitals NHS Foundation Trust. Co-author of UK RCPath Endocrine Cancer Datasets, Thyroid Cytology Guidance document, Endocrine Tissue Pathways and Thyroid Cytology Audit Template. Author of publications on thyroid, parathyroid and NET pathology including ongoing thyroid cytology-histology correlation. Member of NCRI Thyroid Cancer Subgroup. Member of expert panel for ICCR datasets for thyroid and parathyroid cancer. President of UKEPS.

  • Professor Jon Wadsley, Sheffield

    Professor Wadsley was appointed as Consultant Clinical Oncologist at Weston Park Hospital, Sheffield in 2004. His clinical interests are in thyroid cancer, neuroendocrine tumours and pancreatic/biliary tract cancers, with a particular interest in molecular radiotherapy. His research mirrors these clinical interests, with a particular focus on thyroid cancer and neuroendocrine tumours. He currently chairs the NCRI Thyroid Cancer Subgroup and is Chief Investigator of the SELIMETRY trial. He is Clinical Director of the Sheffield Cancer Clinical Trials Centre, Cancer Specialty Lead for the Yorkshire and Humber Clinical Research Network and NIHR National Specialty Lead for Radiotherapy and Imaging

  • Professor Giovanni Tallini

    Giovanni Tallini, MD trained in Anatomic Pathology with Dr. J. Rosai in the US, was Faculty at the Department of Pathology of Yale University School of Medicine, and after 15 years in the US moved back to his native country to become Professor of Pathology at the University of Bologna School of Medicine. In addition to routine anatomic pathology commitments, he has set up and currently directs the Molecular Pathology Unit of the regional health care agency (Azienda USL di Bologna) for the Italian NHS. Over the years Dr. Tallini has developed an interest in thyroid gland pathology and pathobiology, a field to which he has made significant contributions. He has been President of the Endocrine Pathology Society, co-editor of the 2014 AFIP Tumor Pathology Atlas for the thyroid gland, working group member for the WHO books Tumors of Endocrine Organs (3d and 4th editions).

  • Dr Ronald Ghossein

    Dr Ronald Ghossein is Attending Pathologist and Director of Head and Neck Pathology at Memorial Sloan-Kettering Cancer Center in New York City. His research focuses on the histologic reclassification of thyroid carcinomas into clinically relevant entities. He was the senior author of the publication that renamed the non-invasive encapsulated follicular variant of papillary carcinoma as non-invasive follicular thyroid neoplasm with papillary like nuclei (NIFTP). He also published extensively on the predictive value of various histologic and molecular parameters such as extent of vascular invasion, extra-thyroid extension, nodal burden and BRAFV600E. He also analyses mouse models used in thyroid cancer pathogenesis.

  • Professor Saba Balasubramanian

    Professor Saba Balasubramanian is an endocrine surgeon and honorary professor at the University of Sheffield. He is lead clinician for thyroid cancer in Sheffield and educational lead for the British Association of Endocrine and Thyroid surgeons. In addition to numerous book chapters, he has published in peer reviewed journals on thyroid, parathyroid, adrenal surgery and breast cancer and is a chief investigator on several translational and clinical research projects. His current research interests include post-surgical hypoparathyroidism (PoSH), use of novel technology for parathyroid identification and preservation and thyroid cancer epidemiology.
    He is currently the chief investigator for the NIHR EME funded multicentre trial on fluorescent imaging of parathyroids (the NIFTy - Near Infra Red Fluorescent Imaging in Thyroid surgery – trial) and co-investigator in the NIHR HTA funded multicentre trial on hemi versus total thyroidectomy in low risk differentiated thyroid cancer (the HoT trial).

  • Dr David Poller

    Dr David Poller is a Consultant Pathologist & Reader in Pathology at The Queen Alexandra Hospital in Portsmouth. His interests are the pathology & cytology of thyroid & endocrine cancer with a number of publications in this area. Dr Poller is Treasurer and Membership Secretary of the UK Endocrine Pathology Society, and is a member of UK RCPath guideline and NCRI research groups that relate to diagnosis of thyroid cancer. He was member of The Endocrine Pathology Society’s NIFTP working group in 2015/6 and frequently lectures on thyroid disease & FNA thyroid cytology.

Supporting Documentation

Please see attached the conference delegate pack and supporting documentation. 

2nd Bi-Annual UK Endocrine Pathology Society/RCPath Endocrine Pathology Update (EPU) - Delegate Pack